专利检索 ap:("Yukin Therapeutics" OR "Institut National de la Santé et de la Recherche Médicale (INSERM)" OR "Centre Hospitalier Universitaire de Nice (CHU Nice)" OR "Université Côte d'Azur" OR "Centre National de la Recherche Scientifique (CNRS)") AND inv:"Dao, Pascal" 第 1 页

1.

发明公开
SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS 审中-公开

公开(公告)号：EP4169904A1

公开(公告)日：2023-04-26

申请号：EP21315226.7

申请日：2021-10-25

申请人： Yukin Therapeutics , Institut National de la Santé et de la Recherche Médicale (INSERM) , Centre Hospitalier Universitaire de Nice (CHU Nice) , Université Côte d'Azur , Centre National de la Recherche Scientifique (CNRS)

发明人： Houacine, Jemila , Dao, Pascal , Passeron, Thierry , Beranger, Guillaume , Benhida, Rachid , Gourhant, Mathilde , Foussat, Arnaud

IPC分类号： C07D215/44 , C07D401/04 , A61P35/00 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D487/08 , C07D487/10 , A61K31/4706 , A61P37/00

摘要： The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as NF-κB-inducing kinase (NIK) inhibitors and, in particular, can induce the intracellular degradation of NIK, which renders these compounds highly advantageous for use in therapy, including in the treatment or prevention of cancer, inflammatory diseases and autoimmune diseases.